via University of Virginia School of Medicine
A common antidepressant could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.
UVA’s Bradley D. Gelfand and collaborators have found early evidence that the drug fluoxetine – marketed as Prozac – may be effective against atrophic (or “dry”) age-related macular degeneration, a condition that affects nearly 200 million people worldwide. The drug has shown promise in the scientists’ lab tests and animal models, and the researchers bolstered their results by examining two huge insurance databases encompassing more than 100 million Americans. That analysis concluded that patients taking fluoxetine for depression were less likely to develop atrophic macular degeneration.
Based on their findings, the researchers are urging clinical trials to test the drug in patients with AMD. If successful, they believe the drug could be administered either orally or via a long-lasting implant in the eye.
“These findings are an exciting example of the promise of drug repurposing – using existing medicines in new and unexpected ways,” Gelfand, of UVA’s Center for Advanced Vision Science, said. “Ultimately, the best way to test whether fluoxetine benefits macular degeneration is to run a prospective clinical trial.”
Fluoxetine and AMD
The researchers believe fluoxetine works against AMD by binding with a particular agent of the immune system known as an inflammasome. This inflammasome, NLRP3-ASC, triggers the breakdown of the pigmented layer of the eye’s retina.
After conducting extensive bench research, Gelfand and his team tested fluoxetine and eight other depression drugs in lab mice to see what effect, if any, the drugs would have in a model of AMD. Fluoxetine slowed the progression of the disease, but the others did not, the scientists found.
Encouraged by their findings, the researchers looked at fluoxetine use among patients over age 50 in two enormous insurance databases. People taking the drug had a “significantly” slower rate of developing dry AMD, the researchers report in a new scientific paper outlining their findings.
They note that their approach, combining bench research with big-data analysis, could potentially facilitate the repurposing of existing drugs for many conditions, speeding new treatments to patients.
“Traditional approaches to drug development can be expensive and time-consuming: On average, a new FDA-approved drug takes 10 to 12 years and costs $2.8 billion (present-day dollars) to develop,” the researchers wrote. “Our identification of the unrecognized therapeutic activity of an existing FDA-approved drug using big data mining, coupled with demonstrating its efficacy in a disease-relevant model, could greatly accelerate and reduce the cost of drug development.”
Gelfand was involved earlier this year in using a similar approach to determine that HIV drugs known as nucleoside reverse transcriptase inhibitors, or NRTIs, may be useful against dry macular degeneration as well.
“While we have had a great deal of success with the approach of using real-world patient data, we may have only begun to scratch the surface of finding new uses for old drugs,” said Gelfand, of UVA’s departments of Ophthalmology and Biomedical Engineering. “It is tempting to think about all the untapped therapeutic potential of medicines sitting on pharmacy shelves.”
Original Article: PROZAC PEGGED AS POTENTIAL FIRST TREATMENT FOR A LEADING CAUSE OF BLINDNESS
More from: University of Virginia School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug repurposing
- Common heartburn drugs taken by millions ‘increase the risk of agonising brain attacks’
HEARTBURN drugs could increase your risk of agonising migraines, a study shows. People who take acid reflux meds are more likely to suffer severe headaches than those who don’t, US researchers ...
- What Is Drug Repurposing And Why Is It A Game-Changer In Regenerative Medicine?
Repurposed drugs have already undergone rigorous testing for safety and efficacy in other medical conditions. It enables researchers to fast-track their investigations, saving time and resources.
- Drug Repurposing Market Projected to Reach USD 51.8 Billion by 2033, Driven by 4.5% CAGR | Market.us
According to a recent report by Market.us, the Global Drug Repurposing Market size is expected to be worth around USD 51.8 Billion by 2033 from USD 32.1 Billion in 2023, growing at a CAGR of 4.5% ...
- Hyundai to advance cancer study plans for niclosamide-based drug
The niclosamide-based candidate has been repurposed as a cancer treatment by Hyundai and CNPharm after being originally developed for Covid-19.
- A cheap drug may slow down aging. A study will determine if it works
Studies suggest people who take metformin for diabetes may be at lower risk for cancer, heart disease and dementia. Now researchers aim to test if it prevents age-related diseases in healthy people.
Go deeper with Google Headlines on:
Drug repurposing
[google_news title=”” keyword=”drug repurposing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Fluoxetine and AMD
- Over-the-counter eye drops safe to use with AMD medication
Is it safe to use over-the-counter eye drops? I also take Zyrtec nightly for my interstitial cystitis. -- C.H. ANSWER: Eylea is used to treat several cancers as well as the "wet" form of AMD. Eylea ...
- Strides Pharma obtains FDA OK for generic Prozac
Fluoxetine is used for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder, with or without agoraphobia.
Go deeper with Google Headlines on:
Fluoxetine and AMD
[google_news title=”” keyword=”Fluoxetine and AMD” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]